| [1] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志. 2018,21: 177-186.
|
| [2] |
Wang XJ, Malhi H.Nonalcoholic fatty liver disease. Ann Intern Med. 2018, 9: 65-80.
|
| [3] |
Jennison E, Patel J, Scorletti E, et al.Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019, 95: 314-322.
|
| [4] |
Drescher HK, Weiskirchen S, Weiskirchen R.Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cells. 2019, 8: 845.
|
| [5] |
Castera L, Friedrich-Rust M, Loomba R.Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019, 156: 1264-1281.
|
| [6] |
Wong VW, Adams LA, de Lédinghen V, et al. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018, 15: 461-478.
|
| [7] |
Aida Y, Abe H, Tomita Y, et al.Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int [J] Clin Exp Med. 2014, 7: 4191-4198.
|
| [8] |
Darweesh SK, AbdElAziz RA, Abd-ElFatah DS, et al. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. Eur [J] Gastroenterol Hepatol. 2019, 31: 633-641.
|
| [9] |
Huang J, Yeh M, Huang C, et al.Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. PLoS One. 2017, 12: e174394.
|
| [10] |
Verhaegh P, Bavalia R, Winkens B, et al.Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018, 16: 837-861.
|
| [11] |
Boursier J, Anty R, Vonghia L, et al.Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther. 2018, 47: 1387-1396.
|
| [12] |
Zimmermann E, Anty R, Tordjman J, et al.C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. [J] Hepatol. 2011, 55: 660-665.
|
| [13] |
Ponziani FR, Bhoori S, Castelli C, et al.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019, 69: 107-120.
|
| [14] |
Glass O, Henao R, Patel K, et al.Serum interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2018, 2: 1344-1355.
|
| [15] |
Ajmera V, Perito ER, Bass NM, et al.Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology, 2016, 65: 65-77.
|
| [16] |
Zhou J, Cai J, She Z, et al.Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World [J] Gastroenterol. 2019, 25: 1307-1326.
|
| [17] |
Zhang X, Shen J, Man K, et al.CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. [J] Hepatol. 2014, 61: 1365-1375.
|
| [18] |
He L, Deng L, Zhang Q, et al.Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Res Int. 2017, 2017: 1-12.
|
| [19] |
邴浩,李异玲.非酒精性脂肪性肝病的相关基因学概述. 胃肠病学和肝病学杂志. 2019, 28: 835-838.
|
| [20] |
Dai G, Liu P, Li X, et al.Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity. Medicine (Baltimore). 2019, 98: e14324.
|
| [21] |
Sun DQ, Zheng KI, Xu G, et al.PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int, 2020,40:107-119.
|
| [22] |
Pirola CJ, Fernández Gianotti T, Casta?o GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015, 64: 800-812.
|
| [23] |
Hernaez R, Lazo M, Bonekamp S, et al.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011, 54: 1082-1090.
|
| [24] |
Tovo CV, Villela-Nogueira CA, Leite NC, et al.Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2019, 18: 445-449.
|
| [25] |
Pu K, Wang Y, Bai S, et al.Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019, 19: 51.
|
| [26] |
高琪,王付言,张晏境,等.氢质子MR波谱及多回波Dixon技术对非酒精性脂肪性肝病脂肪变定量诊断及分级的价值. 中华放射学杂志. 2018,52: 677-680.
|
